Literature DB >> 32377264

Renal Potassium Excretion Visualized on 82Rubidium PET/CT.

Mads Ryø Jochumsen1,2, Lars Poulsen Tolbod1,2, Michael Borre2,3, Jørgen Frøkiær1,2, Kirsten Bouchelouche1,2, Jens Sörensen1,2.   

Abstract

The positron emission tomography (PET) flow tracer 82Rubidium is a known potassium analogue. During our studies of tumor blood flow in prostate cancer, we found that approximately 10% of the patients had high urinary 82Rubidium activity. In roughly half of these patients, the increased renal rubidium/potassium excretion was either causing hypokalemia or explained by Thiazide treatment. In the other half, there was no obvious explanation or clinical consequence of the renal rubidium/potassium excretion. This is the first time enhanced renal potassium excretion is visualized on 82Rubidium PET/CT. © Korean Society of Nuclear Medicine 2020.

Entities:  

Keywords:  82Rubidium; Hypokalemia; PET; Potassium; Prostate cancer; Renal excretion

Year:  2020        PMID： 32377264      PMCID： PMC7198679          DOI： 10.1007/s13139-020-00637-8

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN： 1869-3474


  12 in total

1.  Comparison of renal excretion of rubidium and potassium.

Authors:  A S KUNIN; E H DEARBORN; B A BURROWS; A S RELMAN
Journal:  Am J Physiol       Date:  1959-12

2.  Extracardiac abnormalities on rubidium-82 cardiac positron emission tomography/computed tomography.

Authors:  Sahar Mirpour; Amir H Khandani
Journal:  Nucl Med Commun       Date:  2011-04       Impact factor: 1.690

3.  FDG and (82)Rb PET/MRI features of brain metastasis of breast cancer.

Authors:  Yang Lu
Journal:  Clin Nucl Med       Date:  2015-06       Impact factor: 7.794

4.  Metastatic renal cell carcinoma avid for 82Rb but not 18F-FDG.

Authors:  Venkatesh L Murthy; Richard K J Brown; James R Corbett
Journal:  Clin Nucl Med       Date:  2014-10       Impact factor: 7.794

5.  Initial human experience with Rubidium-82 renal PET/CT imaging.

Authors:  Abdel K Tahari; Paco E Bravo; Arman Rahmim; Frank M Bengel; Zsolt Szabo
Journal:  J Med Imaging Radiat Oncol       Date:  2013-05-22       Impact factor: 1.735

6.  Effect of K depletion on renal K and Rb excretion: evidence for activation of K reabsorption.

Authors:  F X Beck; G Giebisch; K Thurau
Journal:  Kidney Int       Date:  1992-08       Impact factor: 10.612

7.  Effects of intermediate-conductance Ca2+-activated K+ channel modulators on human prostate cancer cell proliferation.

Authors:  Ashutosh S Parihar; Michael J Coghlan; Murali Gopalakrishnan; Char-Chang Shieh
Journal:  Eur J Pharmacol       Date:  2003-06-27       Impact factor: 4.432

8.  Malignant pheochromocytoma of the anterior mediastinum: PET findings with [18F]FDG and 82Rb.

Authors:  D R Neumann; K E Basile; E L Bravo; E Q Chen; R T Go
Journal:  J Comput Assist Tomogr       Date:  1996 Mar-Apr       Impact factor: 1.826

9.  Repeatability of tumor blood flow quantification with 82Rubidium PET/CT in prostate cancer - a test-retest study.

Authors:  Mads Ryø Jochumsen; Kirsten Bouchelouche; Katrine Bødkergaard Nielsen; Jørgen Frøkiær; Michael Borre; Jens Sörensen; Lars Poulsen Tolbod
Journal:  EJNMMI Res       Date:  2019-07-04       Impact factor: 3.138

Review 10.  Story of Rubidium-82 and Advantages for Myocardial Perfusion PET Imaging.

Authors:  Jean-François Chatal; François Rouzet; Ferid Haddad; Cécile Bourdeau; Cédric Mathieu; Dominique Le Guludec
Journal:  Front Med (Lausanne)       Date:  2015-09-11
View more
  1 in total

1.  Tumour blood flow for prediction of human prostate cancer aggressiveness: a study with Rubidium-82 PET, MRI and Na+/K+-ATPase-density.

Authors:  Mads Ryø Jochumsen; Jens Sörensen; Bodil Ginnerup Pedersen; Jens Randel Nyengaard; Søren Rasmus Palmelund Krag; Jørgen Frøkiær; Michael Borre; Kirsten Bouchelouche; Lars Poulsen Tolbod
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-08-18       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.